David Rodman's most recent trade in Mineralys Therapeutics Inc was a trade of 14,058 Common Stock done at an average price of $27.6 . Disclosure was reported to the exchange on July 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.58 per share. | 13 Jul 2026 | 14,058 | 57,733 | - | 27.6 | 387,717 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2026 | 6,349 | 0 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 13 Jul 2026 | 6,349 | 51,384 | - | 26.6 | 168,955 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 13 Jul 2026 | 6,349 | 71,791 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2026 | 4,167 | 79,167 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 13 Jul 2026 | 4,167 | 65,442 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2026 | 3,542 | 109,792 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Jul 2026 | 3,542 | 61,275 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Jul 2026 | 2,171 | 59,904 | - | 16 | 34,736 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.30 per share. | 09 Jul 2026 | 2,171 | 57,733 | - | 30.3 | 65,781 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2026 | 2,171 | 15,194 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.81 per share. | 15 Jun 2026 | 9,890 | 57,095 | - | 23.8 | 235,487 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 15 Jun 2026 | 4,584 | 57,095 | - | 25 | 114,600 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 15 Jun 2026 | 4,167 | 61,262 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 4,167 | 83,334 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 3,542 | 113,334 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 15 Jun 2026 | 3,542 | 66,985 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 15 Jun 2026 | 417 | 61,679 | - | 15.4 | 6,438 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 417 | 3,750 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.93 per share. | 10 Jun 2026 | 6,349 | 63,443 | - | 23.9 | 151,901 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2026 | 6,349 | 6,349 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 10 Jun 2026 | 6,349 | 69,792 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 10 Jun 2026 | 2,170 | 63,443 | - | 25 | 54,250 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2026 | 2,170 | 17,365 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 10 Jun 2026 | 2,170 | 65,613 | - | 16 | 34,720 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 18 May 2026 | 417 | 63,443 | - | 27.5 | 11,488 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 18 May 2026 | 417 | 63,860 | - | 15.4 | 6,438 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 417 | 4,167 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.58 per share. | 11 May 2026 | 14,056 | 63,443 | - | 28.6 | 401,789 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 6,348 | 12,698 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.36 per share. | 11 May 2026 | 6,348 | 69,792 | - | 29.4 | 186,348 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 May 2026 | 6,348 | 76,140 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 4,166 | 87,501 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 11 May 2026 | 4,166 | 77,499 | - | 14.3 | 59,366 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 3,541 | 116,876 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 11 May 2026 | 3,541 | 73,333 | - | 10.2 | 36,118 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 11 May 2026 | 2,171 | 71,963 | - | 16 | 34,736 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 2,171 | 19,535 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 11 May 2026 | 2,171 | 69,792 | - | 29.7 | 64,500 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 416 | 4,584 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 17 Apr 2026 | 416 | 69,792 | - | 31.3 | 13,033 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 17 Apr 2026 | 416 | 70,208 | - | 15.4 | 6,423 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.54 per share. | 13 Apr 2026 | 14,058 | 76,140 | - | 26.5 | 373,087 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2026 | 6,349 | 19,046 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 13 Apr 2026 | 6,349 | 82,489 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.66 per share. | 13 Apr 2026 | 6,348 | 69,792 | - | 27.7 | 175,586 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2026 | 4,167 | 91,667 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 13 Apr 2026 | 4,167 | 90,198 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2026 | 3,542 | 120,417 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Apr 2026 | 3,542 | 86,031 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.38 per share. | 09 Apr 2026 | 2,170 | 76,140 | - | 27.4 | 59,415 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 2,170 | 21,706 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Apr 2026 | 2,170 | 78,310 | - | 16 | 34,720 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.65 per share. | 17 Mar 2026 | 417 | 76,140 | - | 25.6 | 10,696 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 17 Mar 2026 | 417 | 76,557 | - | 15.4 | 6,438 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 417 | 5,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.91 per share. | 12 Mar 2026 | 10,726 | 79,472 | - | 25.9 | 277,922 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Mar 2026 | 6,348 | 88,837 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 6,348 | 25,395 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.37 per share. | 12 Mar 2026 | 6,348 | 82,489 | - | 27.4 | 173,748 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 4,167 | 95,834 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 12 Mar 2026 | 4,167 | 90,198 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 3,542 | 123,959 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 12 Mar 2026 | 3,542 | 86,031 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.37 per share. | 12 Mar 2026 | 3,079 | 76,393 | - | 27.4 | 84,265 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.82 per share. | 12 Mar 2026 | 253 | 76,140 | - | 27.8 | 7,038 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.84 per share. | 09 Mar 2026 | 2,171 | 82,489 | - | 26.8 | 58,270 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Mar 2026 | 2,171 | 84,660 | - | 16 | 34,736 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 2,171 | 23,876 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 51,300 | 51,300 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 38,400 | 82,489 | - | 0 | Common Stock | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.59 per share. | 17 Feb 2026 | 417 | 44,089 | - | 27.6 | 11,505 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 417 | 5,417 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 17 Feb 2026 | 417 | 44,506 | - | 15.4 | 6,438 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 6,349 | 31,743 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Feb 2026 | 6,349 | 56,786 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.58 per share. | 12 Feb 2026 | 6,348 | 44,089 | - | 27.6 | 175,100 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.94 per share. | 12 Feb 2026 | 5,828 | 50,958 | - | 28.9 | 168,635 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 4,166 | 100,001 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.33 per share. | 12 Feb 2026 | 4,166 | 50,437 | - | 27.3 | 113,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 12 Feb 2026 | 4,166 | 54,603 | - | 14.3 | 59,366 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 3,541 | 127,501 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.33 per share. | 12 Feb 2026 | 3,541 | 50,437 | - | 27.3 | 96,776 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 12 Feb 2026 | 3,541 | 53,978 | - | 10.2 | 36,118 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.64 per share. | 12 Feb 2026 | 521 | 50,437 | - | 29.6 | 15,442 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 2,171 | 26,047 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.21 per share. | 09 Feb 2026 | 2,171 | 50,437 | - | 30.2 | 65,586 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Feb 2026 | 2,171 | 52,608 | - | 16 | 34,736 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.44 per share. | 20 Jan 2026 | 416 | 50,853 | - | 15.4 | 6,423 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 416 | 5,834 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.10 per share. | 20 Jan 2026 | 416 | 50,437 | - | 32.1 | 13,354 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.61 per share. | 13 Jan 2026 | 11,367 | 50,437 | - | 32.6 | 370,645 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.75 per share. | 13 Jan 2026 | 7,709 | 61,804 | - | 32.8 | 252,470 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 13 Jan 2026 | 4,167 | 69,513 | - | 14.3 | 59,380 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 4,167 | 104,167 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Jan 2026 | 3,542 | 65,346 | - | 10.2 | 36,128 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 3,542 | 131,042 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 09 Jan 2026 | 6,348 | 68,152 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.32 per share. | 09 Jan 2026 | 6,348 | 61,804 | - | 32.3 | 205,143 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 6,348 | 38,092 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 09 Jan 2026 | 2,170 | 61,804 | - | 33.3 | 72,196 | Common Stock |